In context
Nangibotide was tested in the randomised phase 2b ASTONISH trial in patients with septic shock. The study investigated treatment effects and a biomarker-based patient-selection strategy. [1]
At a glance
- Type
- Peptide / related clinical research
- Regulatory context
- The cited source describes research, not a determination of present marketing authorisation. Country, formulation and indication must be checked separately.
- Evidence
- Septic shock is an intensive-care emergency. Biomarker-defined hypotheses require validation and do not imply a general anti-inflammatory or wellness use.
How to interpret this evidence
Septic shock is an intensive-care emergency. Biomarker-defined hypotheses require validation and do not imply a general anti-inflammatory or wellness use. [1]
Safety and clinical context
The evidence described here does not establish safety for unsupervised use. Product identity, route, formulation, interactions and long-term effects cannot be inferred from a study category.
Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.
Primary sources
Read the underlying source and its limitations. A study citation does not by itself establish efficacy or approval.